Company Overview and News

Alice Queen hits high-grade gold in new prospect at Horn Island

Alice Queen Ltd (ASX:AQX) has received high-grade gold results from initial drilling of Southern Silicified Ridge prospect at its Horn Island Gold Project in Torres Strait, North Queensland.

Alice Queen eyes resource expansion at Horn Island gold project

Alice Queen Ltd (ASX:AQX) has commenced Phase 2 diamond drilling at its flagship Horn Island gold project in the Torres Strait region of North Queensland.

Spitfire Materials’ shares rise on commencing gold drilling at Alice River

Spitfire Materials Ltd (ASX:SPI) has commenced its maiden drilling program at the Alice River gold project in Queensland.

Alice Queen to lift cash balance

Alice Queen (ASX:AQX) has been granted a trading halt by the ASX, with its shares placed in pre-open. The company is heading to market with a capital raising. Alice Queen recently engaged Mining Plus to undertake gold mineralisation modelling on targets within and in proximity to the historic Horn Island Pit prospect area. Horn Island lies in the Kaurareg Archipelago of the Torres Strait, north of Cape York Peninsula.

Alice Queen to reveal partner

Alice Queen (ASX:AQX) is preparing to outline details of a proposed joint venture, with the ASX granting the company a trading halt to prepare.

Alice Queen Ltd to explore additional copper-gold porphyry targets

The new licence, known as “Mendooran”, continues the company’s strategy of exploring for copper-gold porphyry deposits along the highly prospective Molong Volcanic Belt. The Mendooran target was selected by the company’s chief technical advisor, John Holliday, who was a principal discoverer of Newcrest Mining Ltd’s (ASX:NCM) giant Cadia Valley deposits. Cadia Valley is one of Australia’s largest gold mining operations.

Alice Queen eyes copper-gold anomalies at Looking Glass

The program will consist of two 750 metre holes targeting two discrete magnetic anomalies. The program is supported by a co-funding grant under the New Frontiers Co-operative Drilling Program for up to 50% of the drilling costs, up to the maximum grant amount of $190,000. The Looking Glass tenement lies within the geological and tectonic terrain known as the Lachlan Orogen (formerly Lachlan Fold Belt).

Alice Queen gets ready to drill after oversubscribed placement

Alice Queen Ltd (ASX:AQX) has closed an oversubscribed share placement to raise $868,500 at an issue price of $0.03 per share. The funds raised through the issue will be applied to repay existing liabilities and the ongoing exploration at the company’s flagship Horn Island gold project in the Torres Strait. The potential for a viable operation is being considered after defining a JORC Exploration Target of 100,000 to 190,000 ounces of gold grading 1.

Alice Queen Ltd considering open pit gold mining at Horn Island

Alice Queen Ltd (ASX:AQX) has indicated the potential for a small scale open pit mining operation at its Horn Island Gold Project in the Torres Strait, Queensland. The potential for a viable operation has been considered after defining a JORC Exploration Target of 100,000 to 190,000 ounces of gold grading 1.6 to 2.4 g/t gold for the Pioneer Lode. The Pioneer Lode has been modelled to a maximum depth of 170 metres below surface and consists of mineralisation intersected from the phase 1 drilling program.

Alice Queen Ltd in cash raiser for Horn Island gold project

Horn Island gold hopeful, Alice Queen Ltd (ASX:AQX) will look to raise about $860,000 through a placement at $0.03 each for a new drilling program. The first found gold mineralisation at the Torres Strait islands project off the tip of Australia but the grades as a whole were sub-economic. However, certain zones of mineralisation within the mineralised wedge appear to be potentially economic grade.

Quarterly Activities Report


Quarterly Cashflow Report


Half Yearly Report and Accounts


Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...